Abstract Background Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is widely used for glycaemic control in type 2 diabetes and has demonstrated additional benefits in reducing blood pressure. While the antihypertensive effects of SGLT2 inhibitors are well recognised, there is a gap in understanding the specific impact of dapagliflozin on blood pressure. Purpose This meta-analysis aimed to quantify the effects of dapagliflozin 10 mg on blood pressure in patients with type 2 diabetes and hypertension. Methods We performed a systematic search of the literature in PubMed, Cochrane Library, and Embase to identify relevant randomised clinical trials (RCTs). The primary outcomes were office systolic blood pressure (SBP) and diastolic blood pressure (DBP), while secondary outcomes included 24-hour SBP and DBP. Effect sizes were pooled using a random-effects model in Review Manager (RevMan version 5.4) and reported as mean differences (MD) with 95% confidence intervals (CI). Heterogeneity was assessed using the I² statistic. Results A total of seven RCTs, including 20,308 patients, were included in this meta-analysis. The pooled analysis showed that dapagliflozin significantly reduced office SBP (MD -3.08 mmHg, 95% CI -3.45 to -2.71; p 0.00001; I² = 0%; Figure 1A) and office DBP (MD -1.10 mmHg, 95% CI -1.86 to -0.34; p = 0.004; I² = 0%; Figure 1B). Similar reductions were observed in 24-hour SBP (MD -3.53 mmHg, 95% CI -5.03 to -2.03; p 0.00001; I² = 0%; Figure 2A) and 24-hour DBP (MD -2.13 mmHg, 95% CI -3.58 to -0.67; p = 0.004; I² = 11%; Figure 2B). The low heterogeneity across outcomes further supports the robustness of these findings. Conclusion Dapagliflozin consistently reduced blood pressure in both office and 24-hour measurements, reinforcing its role as an adjunctive therapy in the management of hypertension in type 2 diabetes. Further studies are warranted to assess its long-term cardiovascular benefits.Figure 1 Figure 2
Barbosa et al. (2025) studied this question.